Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GNFTNASDAQ:INBXNYSE:RCORNASDAQ:TIL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGNFTGENFIT$4.02-1.6%$4.06$2.55▼$6.42$203.86M1.1510,690 shs825 shsINBXInhibrx Biosciences$15.21+4.2%$12.65$10.80▼$17.79$211.35MN/A104,110 shs53,361 shsRCORRenovacor$3.20$3.07$1.34▼$9.74$55.26M-0.2830,033 shsN/ATILInstil Bio$28.58+2.6%$20.87$9.62▼$92.00$182.67M2.27176,973 shs213,153 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGNFTGENFIT-2.41%-5.51%-3.92%+12.49%-3.92%INBXInhibrx Biosciences+4.18%+3.61%+21.97%+7.87%+4.39%RCORRenovacor0.00%0.00%0.00%0.00%0.00%TILInstil Bio+2.62%-21.83%+69.11%+45.00%+189.86%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGNFTGENFIT2.3285 of 5 stars3.55.00.00.01.90.00.0INBXInhibrx Biosciences2.4795 of 5 stars0.03.00.04.60.02.51.3RCORRenovacorN/AN/AN/AN/AN/AN/AN/AN/ATILInstil Bio2.2191 of 5 stars3.52.00.00.00.03.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGNFTGENFIT 3.00Buy$13.00223.71% UpsideINBXInhibrx Biosciences 2.00HoldN/AN/ARCORRenovacor 0.00N/AN/AN/ATILInstil Bio 3.00Buy$119.00316.38% UpsideCurrent Analyst Ratings BreakdownLatest RCOR, TIL, INBX, and GNFT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/5/2025TILInstil BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$125.00 ➝ $125.006/2/2025TILInstil BioJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform5/22/2025TILInstil BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$110.00 ➝ $105.005/15/2025INBXInhibrx BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGNFTGENFIT$76.77M2.62$0.07 per share58.30$1.50 per share2.68INBXInhibrx Biosciences$200K1,101.20$117.00 per share0.13$9.23 per share1.65RCORRenovacorN/AN/AN/AN/A$2.47 per shareN/ATILInstil BioN/AN/AN/AN/A$25.96 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGNFTGENFIT$1.63MN/A0.00N/AN/AN/AN/AN/A7/24/2025 (Estimated)INBXInhibrx Biosciences$1.69B$116.750.13N/AN/AN/A-85.12%-58.90%8/12/2025 (Estimated)RCORRenovacor-$14.10M-$0.73N/AN/AN/AN/A-62.88%-48.90%N/ATILInstil Bio-$74.14M-$11.97N/AN/AN/AN/A-45.52%-29.23%8/12/2025 (Estimated)Latest RCOR, TIL, INBX, and GNFT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q4 2024INBXInhibrx Biosciences-$2.55-$2.80-$0.25-$2.80N/AN/A5/13/2025Q1 2025TILInstil Bio-$2.02-$4.32-$2.30-$4.32N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGNFTGENFITN/AN/AN/AN/AN/AINBXInhibrx BiosciencesN/AN/AN/AN/AN/ARCORRenovacorN/AN/AN/AN/AN/ATILInstil BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGNFTGENFIT0.081.231.23INBXInhibrx Biosciences1.045.125.12RCORRenovacorN/A6.606.60TILInstil Bio0.5830.3330.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGNFTGENFIT2.24%INBXInhibrx Biosciences82.46%RCORRenovacor45.84%TILInstil Bio60.56%Insider OwnershipCompanyInsider OwnershipGNFTGENFIT4.20%INBXInhibrx Biosciences17.09%RCORRenovacor14.40%TILInstil Bio47.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGNFTGENFIT12050.00 million47.90 millionNot OptionableINBXInhibrx Biosciences16614.48 million12.00 millionOptionableRCORRenovacor1917.27 million14.78 millionNot OptionableTILInstil Bio4106.56 million3.46 millionNo DataRCOR, TIL, INBX, and GNFT HeadlinesRecent News About These CompaniesWall Street Analysts Think Instil Bio (TIL) Could Surge 246.68%: Read This Before Placing a BetJune 16 at 10:56 AM | zacks.comInstil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody ProgramJune 11, 2025 | globenewswire.comAre You Looking for a Top Momentum Pick? Why Instil Bio, Inc. (TIL) is a Great ChoiceJune 4, 2025 | zacks.comInstil Bio appoints new Chief Medical OfficerJune 4, 2025 | uk.investing.comInstil Bio appoints Jamie Freedman as Chief Medical OfficerJune 2, 2025 | msn.comInstil Bio, Inc. Appoints Jamie Freedman, M.D., Ph.D., as Chief Medical Officer to Propel Cancer Therapy DevelopmentJune 2, 2025 | quiverquant.comInstil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical OfficerJune 2, 2025 | globenewswire.comInstil Bio to Participate in the 2025 Jefferies Global Healthcare ConferenceMay 30, 2025 | globenewswire.comInstil Bio (TIL) Upgraded to Buy: What Does It Mean for the Stock?May 29, 2025 | zacks.comWall Street Analysts Believe Instil Bio (TIL) Could Rally 343.63%: Here's is How to TradeMay 29, 2025 | zacks.comInstil Bio: Second-Half 2025 AXN-2510 Data Could Mark Another PD-1/VEGF SuccessMay 25, 2025 | seekingalpha.comInstil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ...May 25, 2025 | morningstar.comInstil Bio stock price target cut to $105 by H.C. WainwrightMay 24, 2025 | uk.investing.comInstil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in ...May 24, 2025 | seekingalpha.comInstil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in ChicagoMay 23, 2025 | globenewswire.comInstil Bio Shares Jump on Trial Updates for Lung Cancer TreatmentMay 23, 2025 | marketwatch.comInstil Bio shares rise on immunotherapy trial updatesMay 23, 2025 | msn.comInstil Bio shares rise after updates on cancer trialsMay 23, 2025 | seekingalpha.comInstil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025May 22, 2025 | globenewswire.comInstil Bio, Inc. Progresses with Ongoing NSCLC Trials for AXN-2510/IMM2510 and Reports Q1 2025 Financial ResultsMay 13, 2025 | quiverquant.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAmong the Market’s Most Shorted: 2 Firms With +40% Short InterestBy Leo Miller | June 3, 2025View Among the Market’s Most Shorted: 2 Firms With +40% Short Interest3 Stocks Getting Rare Double Upgrades From AnalystsBy Chris Markoch | June 6, 2025View 3 Stocks Getting Rare Double Upgrades From AnalystsBreakout Momentum Plays You May Not Know AboutBy Nathan Reiff | June 6, 2025View Breakout Momentum Plays You May Not Know AboutAST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!By Thomas Hughes | June 16, 2025View AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!3 High-Paying Dividend Stocks That Still Have Safe PayoutsBy Chris Markoch | May 27, 2025View 3 High-Paying Dividend Stocks That Still Have Safe PayoutsRCOR, TIL, INBX, and GNFT Company DescriptionsGENFIT NASDAQ:GNFT$4.01 -0.07 (-1.59%) As of 06/18/2025 03:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.Inhibrx Biosciences NASDAQ:INBX$15.21 +0.61 (+4.18%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$15.25 +0.04 (+0.26%) As of 06/18/2025 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.Renovacor NYSE:RCORRenovacor, Inc., a biotechnology company, focuses on delivering various precision therapies to enhance the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. It primarily focuses on the treatment of BCL2-associated athanogene 3 (BAG3) mutation-associated dilated cardiomyopathy (DCM). The company's lead product candidate is REN-001, a recombinant adeno-associated virus 9-based gene therapy designed to deliver a functional BAG3 gene to augment BAG3 protein levels in cardiomyocytes, and slow or halt progression of BAG3 DCM. It is also developing a pipeline of BAG3-associated gene therapies for diseases with high unmet medical need associated with mutations in the BAG3 gene and mechanistically linked to BAG3's expression and function. The company was founded in 2013 and is based in Greenwich, Connecticut.Instil Bio NASDAQ:TIL$28.58 +0.73 (+2.62%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$28.42 -0.16 (-0.56%) As of 06/18/2025 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Chime’s Smart IPO: Half the Valuation, Double the Strength Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Tesla Bulls and Bears Collide: What Investors Should Know Qualcomm: A Technical Setup Is Emerging, and It's Bullish 330% Returns YTD: Is CoreWeave's Momentum Softening? Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated Microsoft-OpenAI Rift May Cap Stock Upside Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
